atc_code|tarpsy_only|compound_de|addition|constraints_de|constraints_fr|constraints_it|application|unit|since A07AA12|F|Fidaxomicin|||||O|mg|2015 B01AB02|F|Antithrombin III|||||IV|U|2010 B01AC21|F|Treprostinil|||||IV,SC|mg|2016 B01AD12|F|Protein C|||||IV,SC|U|2018 B01AX01|F|Defibrotid|||||O,IV,IM|mg|2017 B02BB01|F|Fibrinogen, human|||||IV|g|2010 B02BD01|F|Blutgerinnungsfaktoren IX, II, VII und X in Kombination|||||IV|U|2010 B02BD02|F|Blutgerinnungsfaktor VIII|Rec,Plas||||IV|U|2010 B02BD03|F|Faktor-VIII-Inhibitor-bypass-Aktivität|||||IV|U|2010 B02BD04|F|Blutgerinnungsfaktor IX|CAI,CBB||||IV|U|2010 B02BD05|F|Blutgerinnungsfaktor VII|||||IV|U|2010 B02BD06|F|Von Willebrand-Faktor und Blutgerinnungsfaktor VIII in Kombination|||||IV|U|2010 B02BD07|F|Blutgerinnungsfaktor XIII|||||IV|U|2010 B02BD08|F|Blutgerinnungsfaktor VIIa|||||IV|mg|2010 B02BD10|F|Von Willebrand-Faktor|||||IV|U|2016 B02BD14|F|Susoctocog alfa|||||IV|U|2017 B02BX04|F|Romiplostim|||||SC|mcg|2012 B06AC01|F|C1-Inhibitor, aus Plasma gewonnen|||||IV|U|2013 C01CX08|F|Levosimendan|||||IV|mg|2012 C02KX01|F|Bosentan|||||O|mg|2010 C02KX02|F|Ambrisentan|||||O|mg|2012 C02KX04|F|Macitentan|||||O|mg|2017 C02KX05|F|Riociguat|||||O|mg|2017 D03BA03|F|Bromelain|||||T|g|2018 H01BA04|F|Terlipressin|||||IV|mg|2010 J02AA01|F|Amphotericin B||liposomal IV|forme liposomale i.v. |Liposomiale e.v.|IV|mg|2010 J02AC03|F|Voriconazol|Susp,Tab||||O,IV|mg|2010 J02AC04|F|Posaconazol|Susp,Tab||||O,IV|mg|2010 J02AC05|F|Isavuconazol|||||O,IV|mg|2017 J05AP07|F|Daclatasvir|||||O|mg|2017 J05AP08|F|Sofosbuvir|||||O|mg|2016 J05AP09|F|Dasabuvir|||||O|mg|2016 J05AP51|F|Sofosbuvir und Ledipasvir|CHV||||O|UD|2016 J05AP53|F|Ombitasvir, Paritaprevir und Ritonavir|CVK||||O|UD|2016 J05AP54|F|Elbasvir und Grazoprevir|CZR||||O|UD|2017 J05AP55|F|Sofosbuvir und Velpatasvir |CEP||||O|UD|2018 J05AP56|F|Sofosbuvir, Velpatasvir und Voxilaprevir|CVO||||O|UD|2018 J05AP57|F|Glecaprevir und Pibrentasvir|CMA||||O|UD|2018 J02AX01|F|Flucytosin|||||IV|mg|2016 J02AX04|F|Caspofungin|||||IV|mg|2010 J02AX05|F|Micafungin|||||IV|mg|2012 J02AX06|F|Anidulafungin|||||IV|mg|2010 J06BA02|F|Immunglobuline, normal human, zur intravasalen Anwendung|||||IV|g|2010 J06BB04|F|Hepatitis-B-Immunglobulin|||||IM,IV,SC|U|2013 J06BB09|F|Cytomegalievirus-Immunglobulin|||||IV|U|2010 J06BB16|F|Palivizumab|||||IM|mg|2010 L01AB01|F|Busulfan|||||O,IV|mg|2010 L01BA04|F|Pemetrexed|||||IV|mg|2010 L01BA05|F|Pralatrexat|||||IV|mg|2015 L01BB04|F|Cladribin|||||IV,SC|mg|2010 L01BB06|F|Clofarabin|||||IV|mg|2010 L01BB07|F|Nelarabin|||||IV|mg|2010 L01BC07|F|Azacitidin|||||IV,SC|mg|2012 L01BC08|F|Decitabin|||||IV|mg|2016 L01CX01|F|Trabectedin|||||IV|mg|2013 L01XC02|F|Rituximab|||||IV,SC|mg|2010 L01XC03|F|Trastuzumab|||||IV,SC|mg|2010 L01XC06|F|Cetuximab|||||IV|mg|2010 L01XC07|F|Bevacizumab|||||IV|mg|2010 L01XC08|F|Panitumumab|||||IV|mg|2012 L01XC10|F|Ofatumumab|||||IV|mg|2014 L01XC11|F|Ipilimumab|||||IV|mg|2017 L01XC12|F|Brentuximab vedotin|||||IV|mg|2014 L01XC13|F|Pertuzumab|||||IV|mg|2014 L01XC14|F|Trastuzumab emtansin|||||IV|mg|2014 L01XC15|F|Obinutuzumab|||||IV|mg|2017 L01XC17|F|Nivolumab|||||IV|mg|2017 L01XC18|F|Pembrolizumab|||||IV|mg|2017 L01XC19|F|Blinatumomab|||||IV|mcg|2017 L01XC23|F|Elotuzumab|||||IV|mg|2017 L01XC24|F|Daratumumab|||||IV|mg|2017 L01XC27|F|Olaratumab|||||IV|mg|2018 L01XE02|F|Gefitinib|||||O|mg|2013 L01XE03|F|Erlotinib|||||O|mg|2013 L01XE04|T|Sunitinib|||||O|mg|2010 L01XE05|T|Sorafenib|||||O|mg|2010 L01XE06|T|Dasatinib|||||O|mg|2010 L01XE08|T|Nilotinib|||||O|mg|2010 L01XE11|F|Pazopanib|||||O|mg|2013 L01XE12|T|Vandetanib|||||O|mg|2018 L01XE15|F|Vemurafenib|||||O|mg|2013 L01XE16|F|Crizotinib|||||O|mg|2015 L01XE17|F|Axitinib|||||O|mg|2013 L01XE23|F|Dabrafenib|||||O|mg|2015 L01XE25|F|Trametinib|||||O|mg|2017 L01XE26|F|Cabozantinib|||||O|mg|2018 L01XE27|F|Ibrutinib|||||O|mg|2016 L01XE28|F|Ceritinib|||||O|mg|2017 L01XE29|F|Lenvatinib|||||O|mg|2017 L01XE31|F|Nintedanib|||||O|mg|2017 L01XE38|F|Cobimetinib|||||O|mg|2017 L01XE39|F|Midostaurin|||||O|mg|2018 L01XX01|F|Amsacrin|||||IM,IV|mg|2010 L01XX02|F|Asparaginase|||||IM,IV|U|2010 L01XX24|F|Pegaspargase|||||IM,IV|U|2013 L01XX27|F|Arsentrioxid|||||IV|mg|2012 L01XX32|F|Bortezomib|||||IV,SC|mg|2010 L01XX42|F|Panobinostat|||||O|mg|2017 L01XX43|F|Vismodegib|||||O|mg|2015 L01XX45|F|Carfilzomib|||||IV|mg|2016 L01XX46|F|Olaparib|||||O|mg|2017 L01XX47|F|Idelalisib|||||O|mg|2016 L01XX51|F|Talimogen laherparepvec|||||IL|U|2018 L02BB04|F|Enzalutamid|||||O|mg|2017 L02BX03|F|Abirateron|||||O|mg|2014 L03AA13|F|Pegfilgrastim|||||SC|mg|2010 L03AX16|F|Plerixafor|||||SC|mg|2012 L04AA03|F|Antilymphozytäres Immunglobulin (Pferd)|||||IV|mg|2010 L04AA04|F|Antithymozytäres Immunglobulin (Kaninchen)|CTG,CFR||||IV|mg|2014 L04AA23|F|Natalizumab|||||IV|mg|2010 L04AA24|F|Abatacept|||||IV,SC|mg|2010 L04AA25|F|Eculizumab|||||IV|mg|2010 L04AA28|F|Belatacept|||||IV|mg|2017 L04AA33|F|Vedolizumab|||||IV|mg|2016 L04AA34|F|Alemtuzumab||Behandlung Multiple Sklerose|pour trait. sclérose en plaques|Trattamento della sclerosi multipla|IV|mg|2010 L04AB01|F|Etanercept|||||SC|mg|2010 L04AB02|F|Infliximab|||||IV|mg|2010 L04AB04|F|Adalimumab|||||IV,SC|mg|2010 L04AB05|F|Certolizumab pegol|||||IV,SC|mg|2010 L04AB06|F|Golimumab|||||IV,SC|mg|2010 L04AC01|T|Daclizumab|||||SC|mg|2018 L04AC05|F|Ustekinumab|||||IV,SC|mg|2012 L04AC07|F|Tocilizumab|||||IV,SC|mg|2010 L04AX04|F|Lenalidomid|||||O|mg|2010 L04AX05|F|Pirfenidon|||||O|mg|2017 L04AX06|F|Pomalidomid|||||O|mg|2016 M09AX07|F|Nusinersen|||||IT|mg|2018 N05AH01|T|Loxapin|||||Inhal,O|mg|2018 N05AH03|T|Olanzapin|CZY|Depotinjektion|injection dépôt|Iniezione deposito|IM|mg|2017 N05AX08|T|Risperidon|CRC|Depotinjektion|injection dépôt|Iniezione deposito|IM|mg|2017 N05AX12|T|Aripiprazol|CAM|Depotinjektion|injection dépôt|Iniezione deposito|IM|mg|2017 N05AX13|T|Paliperidon|CXE|Depotinjektion|injection dépôt|Iniezione deposito|IM|mg|2017 R07AA02|F|Surfactant|||||ET|mg|2010 R07AX02|F|Ivacaftor|||||O|mg|2017 R07AX30|F|Ivacaftor und Lumacaftor|COK||||O|UD|2017 V03AF07|F|Rasburicase|||||IV|mg|2010 V03AF09|F|Glucarpidase|||||IV|U|2017